Institutional members access full text with Ovid®

Share this article on:


Farlow, Martin R.

CONTINUUM: Lifelong Learning in Neurology: April 2007 - Volume 13 - Issue 2, Dementia - p 39-68
doi: 10.1212/01.CON.0000267235.69379.07

Alzheimer's disease (AD) is the most common form of dementia in aging adults. The diagnosis is still primarily made on the basis of history and physical and neurologic examinations. The incidence increases rapidly with age, so the number of affected individuals with AD is ballooning rapidly. Cholinesterase inhibitors are mildly effective in treating cognitive and global functioning, as well as behavior abnormalities in patients with mild-, moderate-, or severe-stage disease. The N-methyl-D-aspartate (NMDA) antagonist memantine is similarly mildly effective alone or in combination with cholinesterase inhibitors in moderate to severe stages of the disease. No therapy is proven to delay disease progression, but recent insights into the pathophysiology of AD have led to promising investigational therapies, including the development of both γ- and β-secretase inhibitors as well as active and passive immunization against the amyloid β-protein. Continuum Lifelong Learning Neurol 2007;13(2):39-68.

© 2007 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website